These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
633 related items for PubMed ID: 37417288
21. 68Ga-PSMA PET/CT based primary staging and histological correlation after extended pelvic lymph node dissection at radical prostatectomy. Kopp J, Kopp D, Bernhardt E, Manka L, Beck A, Gerullis H, Karakiewicz P, Schoerner W, Hammerer P, Schiffmann J. World J Urol; 2020 Dec; 38(12):3085-3090. PubMed ID: 32103332 [Abstract] [Full Text] [Related]
22. Pelvic lymph-node staging with 18F-DCFPyL PET/CT prior to extended pelvic lymph-node dissection in primary prostate cancer - the SALT trial. Jansen BHE, Bodar YJL, Zwezerijnen GJC, Meijer D, van der Voorn JP, Nieuwenhuijzen JA, Wondergem M, Roeleveld TA, Boellaard R, Hoekstra OS, van Moorselaar RJA, Oprea-Lager DE, Vis AN. Eur J Nucl Med Mol Imaging; 2021 Feb; 48(2):509-520. PubMed ID: 32789599 [Abstract] [Full Text] [Related]
23. More advantages in detecting bone and soft tissue metastases from prostate cancer using 18F-PSMA PET/CT. Pianou NK, Stavrou PZ, Vlontzou E, Rondogianni P, Exarhos DN, Datseris IE. Hell J Nucl Med; 2019 Feb; 22(1):6-9. PubMed ID: 30843003 [Abstract] [Full Text] [Related]
24. Diagnostic Accuracy of 64Copper Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography for Primary Lymph Node Staging of Intermediate- to High-risk Prostate Cancer: Our Preliminary Experience. Cantiello F, Gangemi V, Cascini GL, Calabria F, Moschini M, Ferro M, Musi G, Butticè S, Salonia A, Briganti A, Damiano R. Urology; 2017 Aug; 106():139-145. PubMed ID: 28438628 [Abstract] [Full Text] [Related]
25. Prostate-Specific Membrane Antigen PET/CT Combined with Sentinel Node Biopsy for Primary Lymph Node Staging in Prostate Cancer. Hinsenveld FJ, Wit EMK, van Leeuwen PJ, Brouwer OR, Donswijk ML, Tillier CN, Vegt E, van Muilekom E, van Oosterom MN, van Leeuwen FWB, van der Poel HG. J Nucl Med; 2020 Apr; 61(4):540-545. PubMed ID: 31562222 [Abstract] [Full Text] [Related]
26. Robot-Assisted Prostate-Specific Membrane Antigen-Radioguided Surgery in Primary Diagnosed Prostate Cancer. Gondoputro W, Scheltema MJ, Blazevski A, Doan P, Thompson JE, Amin A, Geboers B, Agrawal S, Siriwardana A, Van Leeuwen PJ, van Oosterom MN, Van Leeuwen FWB, Emmett L, Stricker PD. J Nucl Med; 2022 Nov; 63(11):1659-1664. PubMed ID: 35241483 [Abstract] [Full Text] [Related]
27. Accuracy of 68Ga-PSMA PET-CT and PET-MRI in lymph node staging for localized prostate cancer. Barbosa ÁRG, Amaral BS, Lourenço DB, Bianco B, Gushiken FA, Apezzato M, Silva JF, Cunha MLD, Filippi RZ, Baroni RH, Lemos GC, Carneiro A. Einstein (Sao Paulo); 2022 Nov; 20():eAO6599. PubMed ID: 35584444 [Abstract] [Full Text] [Related]
28. Outcomes of Primary Lymph Node Staging of Intermediate and High Risk Prostate Cancer with 68Ga-PSMA Positron Emission Tomography/Computerized Tomography Compared to Histological Correlation of Pelvic Lymph Node Pathology. Yaxley JW, Raveenthiran S, Nouhaud FX, Samartunga H, Yaxley AJ, Coughlin G, Delahunt B, Egevad L, McEwan L, Wong D. J Urol; 2019 Apr; 201(4):815-820. PubMed ID: 30672842 [Abstract] [Full Text] [Related]
29. Prostate-specific membrane antigen Radioguided Surgery to Detect Nodal Metastases in Primary Prostate Cancer Patients Undergoing Robot-assisted Radical Prostatectomy and Extended Pelvic Lymph Node Dissection: Results of a Planned Interim Analysis of a Prospective Phase 2 Study. Gandaglia G, Mazzone E, Stabile A, Pellegrino A, Cucchiara V, Barletta F, Scuderi S, Robesti D, Leni R, Samanes Gajate AM, Picchio M, Gianolli L, Brembilla G, De Cobelli F, van Oosterom MN, van Leeuwen FWB, Montorsi F, Briganti A. Eur Urol; 2022 Oct; 82(4):411-418. PubMed ID: 35879127 [Abstract] [Full Text] [Related]
30. Baseline PSMA-PET/CT as a predictor of PSA persistence following radical prostatectomy in high-risk nonmetastatic prostate cancer patients receiving neoadjuvant therapy. Du X, Dong Y, Liu J, Su Y, Zhu Y, Pan J, Dong B, Chen R, Liu J, Tong Z, Pienta KJ, Rowe SP, Dong L, Xue W. Prostate; 2023 Aug; 83(11):1112-1120. PubMed ID: 37165552 [Abstract] [Full Text] [Related]
31. 68Ga-PSMA Positron Emission Tomography/Computed Tomography Provides Accurate Staging of Lymph Node Regions Prior to Lymph Node Dissection in Patients with Prostate Cancer. Herlemann A, Wenter V, Kretschmer A, Thierfelder KM, Bartenstein P, Faber C, Gildehaus FJ, Stief CG, Gratzke C, Fendler WP. Eur Urol; 2016 Oct; 70(4):553-557. PubMed ID: 26810345 [Abstract] [Full Text] [Related]
32. 68Ga-Labeled Prostate-specific Membrane Antigen Ligand Positron Emission Tomography/Computed Tomography for Prostate Cancer: A Systematic Review and Meta-analysis. von Eyben FE, Picchio M, von Eyben R, Rhee H, Bauman G. Eur Urol Focus; 2018 Sep; 4(5):686-693. PubMed ID: 28753806 [Abstract] [Full Text] [Related]
33. 68Ga-PSMA-11 PET has the potential to improve patient selection for extended pelvic lymph node dissection in intermediate to high-risk prostate cancer. Ferraro DA, Muehlematter UJ, Garcia Schüler HI, Rupp NJ, Huellner M, Messerli M, Rüschoff JH, Ter Voert EEGW, Hermanns T, Burger IA. Eur J Nucl Med Mol Imaging; 2020 Jan; 47(1):147-159. PubMed ID: 31522272 [Abstract] [Full Text] [Related]
34. PSMA PET Scan Era: A Changing Paradigm PSMA PET and Lymph Node Dissection for Prostate Cancer Management. Haxhimolla J, Kua B, Gilbourd D, Haxhimolla H. Semin Oncol Nurs; 2020 Aug; 36(4):151044. PubMed ID: 32723519 [Abstract] [Full Text] [Related]
36. Risk of metastatic disease on 68 gallium-prostate-specific membrane antigen positron emission tomography/computed tomography scan for primary staging of 1253 men at the diagnosis of prostate cancer. Yaxley JW, Raveenthiran S, Nouhaud FX, Samaratunga H, Yaxley WJ, Coughlin G, Yaxley AJ, Gianduzzo T, Kua B, McEwan L, Wong D. BJU Int; 2019 Sep; 124(3):401-407. PubMed ID: 31141284 [Abstract] [Full Text] [Related]
37. 68Ga-Prostate-Specific Membrane Antigen Positron Emission Tomography-Computed Tomography-Based Primary Staging and Histological Correlation after Extended Pelvic Lymph Node Dissection in Intermediate-Risk Prostate Cancer. Kopp D, Kopp J, Bernhardt E, Manka L, Beck A, Gerullis H, Karakiewicz PI, Salomon G, Wiggermann P, Hammerer P, Schiffmann J. Urol Int; 2022 Sep; 106(1):56-62. PubMed ID: 33965965 [Abstract] [Full Text] [Related]
38. Performance characteristics of computed tomography in detecting lymph node metastases in contemporary patients with prostate cancer treated with extended pelvic lymph node dissection. Briganti A, Abdollah F, Nini A, Suardi N, Gallina A, Capitanio U, Bianchi M, Tutolo M, Passoni NM, Salonia A, Colombo R, Freschi M, Rigatti P, Montorsi F. Eur Urol; 2012 Jun; 61(6):1132-8. PubMed ID: 22099610 [Abstract] [Full Text] [Related]
39. Initial Experience of (68)Ga-PSMA PET/CT Imaging in High-risk Prostate Cancer Patients Prior to Radical Prostatectomy. Budäus L, Leyh-Bannurah SR, Salomon G, Michl U, Heinzer H, Huland H, Graefen M, Steuber T, Rosenbaum C. Eur Urol; 2016 Mar; 69(3):393-6. PubMed ID: 26116958 [Abstract] [Full Text] [Related]
40. Rational use of Ga-68 PSMA PET-CT according to nomograms and risk groups for the detection of lymph node metastasis in prostate cancer. Madendere S, Kılıç M, Köseoğlu E, Aykanat İC, Eden AB, Coşkun B, Tekkalan FB, Balbay MD. Urol Oncol; 2024 Feb; 42(2):29.e9-29.e15. PubMed ID: 38114351 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]